The Competition Commission of Singapore (“CCS”) has conducted a post-merger study of the kidney dialysis market over the period December 2012 to June 2015, and has published its findings in a post-action evaluation paper (“Paper”).

The study follows CCS’s decision to clear the acquisition by Asia Renal Care (SEA) Pte Ltd. of Orthe Pte. Ltd. (“Acquisition”) in December 2012. Although the Acquisition resulted in a merged entity Fresenius Medical Care Singapore (“FMC”) with a high combined market share that significantly exceeded 40 per cent, CCS allowed the merger to proceed on the basis that there would not be a substantial lessening of competition.

Read more here.